TD Cowen raised the firm’s price target on Argenx to $533 from $458 and keeps an Outperform rating on the shares. The firm noted its ADHERE CIDP study hits all major endpoints with highly competitive relapse rate in Stage B and 67% response rate in Stage A and supports Vyvgart Hytrulo as a very attractive therapy.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on ARGX:
- argenx announces launch of proposed global offering
- Argenx, Zai Lab Soar on Promising Data in CIDP
- Argenx resumed with an Outperform at Evercore ISI
- Zai Lab, Argenx announce ADHERE study met primary endpoint
- argenx Reports Positive Topline Data from ADHERE Study of VYVGART Hytrulo in Patients with Chronic Inflammatory Demyelinating Polyneuropathy